Moderna has finalised the trial protocol of the Phase III study of its Covid-19 vaccine, mRNA-1273, a significant step towards initiating this late-stage trial.
This trial will be conducted in collaboration with the the National Institute of Allergy and Infectious Diseases (NIAID) and aims to enrol 30,000 participants in the US. The primary endpoint will be preventing symptomatic Covid-19 disease.
The company’s chief medical officer Tal Zaks said: “We look forward to beginning our Phase III study of mRNA-1273 with some 30,000 participants in July.
“Moderna is committed to advancing the clinical development of mRNA-1273 as safely and quickly as possible to demonstrate our vaccine’s ability to significantly reduce the risk of Covid-19 disease.”
Moderna’s latest announcement comes within a few weeks of the first patients being dosed in its Phase II study; the first cohort of adults aged 18-54 has now been fully enrolled.
